TLR9 and neoplasm: Supporting information (SI): characterization of MGNs functionalized with mPEG; CCK-8 cell viability assay in 4T1 cells after STING + TLR9 treatment; CT imaging and ROI of STING + TLR9 treated cohort; tumor weight, spleen weight, immunofluorescence of CD31, and flow cytometry of CD4+ T cells for STING + TLR9 treatment; FACS gating schema; tumor weight, spleen weight, immunofluorescence of CD31, and flow cytometry of CD4+ T cells for antiOX40 treatment; correlation coefficient values for the heatmap comparing marker pairs from ex vivo Raman and IF imaging.